3,4-Methylenedioxymethamphetamine: From Dangerous Party Drug to Potential Therapeutic Agent
DOI:
https://doi.org/10.12775/QS.2026.54.70302Keywords
MDMA, MDMA-Assisted Therapy, PTSD, alcohol dependence, depression, anxiety, mental health of athletic populationsAbstract
Introduction and aim of the study: 3,4-methylenedioxymethamphetamine (MDMA) is a stimulant drug with widespread consumption. It is used mainly in recreational settings, due to its ability to induce various pleasurable, mood-enhancing effects. Prolonged and excessive MDMA misuse can lead to multiple negative outcomes ranging from cognitive dysfunction or emotional dysregulation to severe life-threatening consequences such as hyperthermia. Despite its harmful potential, MDMA presents promising therapeutic applications in MDMA-Assisted Therapy. In this study we aim to review both the dangers and potential psychiatric applications of MDMA.
Materials and methods: A literature search was conducted using databases such as PubMed and Google Scholar. The review focused on peer-reviewed articles and international reports regarding the use of MDMA, both recreational and in the treatment of various psychiatric conditions.
Conclusions: While MDMA has traditionally been associated mainly with recreational use and addiction, research suggests it has the potential to become a valuable therapeutic adjunct in treating such psychiatric conditions as PTSD, alcohol dependence, depression and anxiety. Furthermore, it could be beneficial in the athletic populations. However, existing studies are limited by small sample sizes, highlighting the need for further large-scale research to confirm these findings.
Keywords: MDMA, MDMA-Assisted Therapy, PTSD, alcohol dependence, depression, anxiety, mental health of athletic populations
References
1. United Nations Office on Drugs and Crime. World Drug Report 2025. Vienna: UNODC; 2025.
2. Substance Abuse and Mental Health Services Administration. Results from the 2011 National Survey on Drug Use and Health: Summary of National Findings. Rockville (MD): Substance Abuse and Mental Health Services Administration; 2012. (NSDUH Series H-44; HHS Publication No. SMA 12-4713).
3. Beck C. MDMA – Die frühen Jahre. In: Rätsch C, Baker JR, editors. Jahrbuch für Ethnomedizin und Bewußtseinsforschung 1997/98. Berlin: VWB-Verlag; 2000. p. 95-125.
4. Shulgin AT, Nichols DE. Characterization of three new psychotomimetics. In: Stillman RC, Willette RE, editors. The Psychopharmacology of Hallucinogens. New York: Pergamon Press; 1978. p. 74-83.
5. Adamson S, Metzner R, editors. Through the Gateway of the Heart: Accounts of Experiences with MDMA and Other Empathogens. 2nd ed. San Francisco: Four Trees Publications; 1998. ISBN: 9780963009654.
6. Holland J, editor. Ecstasy: The Complete Guide: A Comprehensive Look at the Risks and Benefits of MDMA. Rochester, VT: Park Street Press; 2001. ISBN: 9780892818570.
7. EcstasyData.org [Internet]. San Francisco: EcstasyData; [cited 2026 Jan 28]. Available from: https://www.ecstasydata.org
8. Liechti ME, Gamma A, Vollenweider FX. Gender differences in the subjective effects of MDMA. Psychopharmacology. 2001;154(2):161-168. https://doi.org/10.1007/s002130000648
9. Rodgers J, Buchanan T, Pearson C, Parrott AC, Ling J, Heffernan T, Scholey AB. Differential experiences of the psychobiological sequelae of ecstasy use: quantitative and qualitative data from an internet study. Journal of Psychopharmacology. 2006;20(3):437-446. https://doi.org/10.1177/0269881105058777
10. Sumnall HR, Cole JC, Jerome L. The varieties of ecstatic experience: an exploration of the subjective experiences of ecstasy. Journal of Psychopharmacology. 2006;20(5):670-682. https://doi.org/10.1177/0269881106060764
11. Green AR, Mechan AO, Elliott JM, O’Shea E, Colado MI. The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, “ecstasy”). Pharmacol Rev. 2003;55(3):463–508. https://doi.org/10.1124/pr.55.3.3
12. Gudelsky GA, Yamamoto BK. Actions of 3,4-methylenedioxymethamphetamine (MDMA) on central serotonergic, dopaminergic and noradrenergic systems. Pharmacol Biochem Behav. 2008;90(2):198–207. https://doi.org/10.1016/j.pbb.2007.10.003
13. Johansen P, Krebs TS. How could MDMA (ecstasy) help anxiety disorders? A neurobiological rationale. J Psychopharmacol. 2009;23(4):389–401. https://doi.org/10.1177/0269881109102787
14. Dumont GJH, Sweep FCGJ, van der Steen R, et al. Increased oxytocin concentrations and prosocial feelings in humans after MDMA administration. Soc Cogn Affect Neurosci. 2009;4(4):359–366. https://doi.org/10.1080/17470910802649470
15. Gamma A, Buck A, Berthold T, Hell D, Vollenweider FX. 3,4-Methylenedioxymethamphetamine (MDMA) modulates cortical and limbic brain activity as measured by [18F]FDG PET. Neuropsychopharmacology. 2000;23(4):388–395. https://doi.org/10.1016/S0893-133X(00)00130-5
16. Kolbrich EA, Goodwin RS, Gorelick DA, et al. Physiological and subjective responses to controlled oral MDMA administration. J Clin Psychopharmacol. 2008;28(4):432–440. https://doi.org/10.1097/JCP.0b013e31817ef470
17. Craig AD. Interoception: The sense of the physiological condition of the body. Trends Cogn Sci. 2003;7(11):500–505. https://doi.org/10.1016/S0959-4388(03)00090-4
18. Pollatos O, Traut-Mattausch E, Schandry R. Differential effects of anxiety and depression on interoceptive accuracy. J Anxiety Disord. 2007;21(4):479–492. https://doi.org/10.1016/j.janxdis.2006.12.004
19. Paulus MP, Stein MB. Interoception in anxiety and depression. Brain Struct Funct. 2010;214(5–6):451–463. https://doi.org/10.1007/s00429-010-0258-9
20. Harshaw C. Interoceptive dysfunction: Toward an integrated framework for understanding somatic and affective disturbance in depression. Psychol Bull. 2015;141(2):311–363. https://doi.org/10.1037/a0038101
21. Walpola IC, McMahon K, Loo C, et al. Altered brain activity following MDMA administration. Neuropsychopharmacology. 2017;42(10):2158–2166. https://doi.org/10.1038/npp.2017.35
22. Ricaurte GA, Yuan J, McCann UD. 3,4-Methylenedioxymethamphetamine (MDMA) neurotoxicity: studies in animals. Neuropsychobiology. 2000;42(1):5–10. https://doi.org/10.1159/000026664
23. Biezonski DK, Meyer JS. Effects of 3,4-methylenedioxymethamphetamine on serotonin neurons. J Neurochem. 2010;113(2):352–361. https://doi.org/10.1111/j.1471-4159.2009.06515.x
24. Biezonski DK, Meyer JS. Neurotoxicity of MDMA and related compounds. CNS Neurol Disord Drug Targets. 2011;10(4):413–423. https://doi.org/10.2174/157015911795017146
25. Parrott AC. MDMA, serotonergic neurotoxicity, and the diverse functional deficits of recreational “ecstasy” users. Neurosci Biobehav Rev. 2013;37(8):1466–1484. https://doi.org/10.1016/j.neubiorev.2013.04.016
26. Cowan RL, et al. Decreased cortical serotonin transporter availability in abstinent MDMA users. Psychopharmacology. 2007;189(3):343–351. https://doi.org/10.1007/s00213-006-0467-3
27. Cowan RL, et al. MDMA use and neuroadaptation. Ann N Y Acad Sci. 2008;1139:291–301. https://doi.org/10.1196/annals.1432.007
28. Gouzoulis-Mayfrank E, Daumann J. Neurotoxicity of MDMA (ecstasy): current status of research. Dialogues Clin Neurosci. 2009;11(3):305–317. https://doi.org/10.31887/DCNS.2009.11.3/egmayfrank
29. Meyer JS. Neurodevelopmental effects of MDMA. Subst Abuse Rehabil. 2013;4:89–98. https://doi.org/10.2147/SAR.S37258
30. Peiró AM, Farré M, Roset PN, et al. Human pharmacology of MDMA. Psychopharmacology. 2002;165(2):175–184. https://doi.org/10.1007/s00213-012-2894-7
31. Farré M, de la Torre R, Mathúna BO, et al. Repeated doses administration of MDMA in humans. Psychopharmacology. 2004;173(3–4):364–375. https://doi.org/10.1007/s00213-004-1789-7
32. Degenhardt L, Bruno R, Topp L. Is ecstasy a drug of dependence? Drug Alcohol Depend. 2010;107(1):1–10. https://doi.org/10.1016/j.drugalcdep.2009.09.009
33. Screaton GR, Cairns JA. Cardiac arrhythmias after MDMA (“ecstasy”). Lancet. 1992;340(8821):1443. https://doi.org/10.1016/0140-6736(92)90834-p
34. Patel MM, Belson MG, Wright RO, Hennes H. Methylenedioxymethamphetamine (ecstasy)-related hyperthermia. J Emerg Med. 2005;29(4):451–456. https://doi.org/10.1016/j.jemermed.2005.05.007
35. de la Torre R, Farré M, Roset PN, et al. Pharmacology of MDMA in humans. Eur J Clin Pharmacol. 2005;61(12):911–918. https://doi.org/10.1007/s00228-005-0965-y
36. Multidisciplinary Association for Psychedelic Studies. MDMA Investigator’s Brochure (MDMA). 13th ed. San Jose (CA): MAPS; 2021.
37. Mitchell JM, Ot’alora G M, van der Kolk B, et al. MDMA-assisted therapy for moderate to severe post-traumatic stress disorder: a randomized, placebo-controlled phase 3 trial. Nat Med. 2023;29(10):2473–2480. https://doi.org/10.1038/s41591-023-02565-4
38. Wolfgang M, et al. MDMA-assisted psychotherapy for post-traumatic stress disorder. Am J Psychiatry. 2024. https://doi.org/10.1176/appi.ajp.20230681
39. U.S. Department of Veterans Affairs. MDMA-assisted therapy for PTSD [Internet]. Washington (DC): U.S. Department of Veterans Affairs; [cited 2026 Jan 31]. Available from: https://www.ptsd.va.gov/understand_tx/mdma_assisted_therapy.asp
40. Zhang X, et al. Advances in MDMA-assisted psychotherapy. CNS Neurol Disord Drug Targets. 2025. https://doi.org/10.2174/0109298673359474250511181821
41. Trautmann S, et al. Psychedelic-assisted psychotherapy. In: Oxford Handbook of Psychiatry. Oxford: Oxford University Press; 2018. https://doi.org/10.1093/med/9780190259440.003.0008
42. Lewis C, Roberts NP, Gibson S, Bisson JI. Dropout rates from psychological therapies for PTSD: systematic review and meta-analysis. Eur J Psychotraumatol. 2020;11(1):1709709. https://doi.org/10.1080/20008198.2019.1709709
43. Alexander W. Pharmacotherapy for post-traumatic stress disorder in combat veterans. P T. 2012;37(1):32–38. PMID:22346334
44. World Health Organization. Global status report on alcohol and health and treatment of substance use disorders 2024 [Internet]. Geneva: World Health Organization; 2024 [cited 2026 Jan 31]. Available from: https://www.who.int/publications/i/item/9789240096752
45. Sessa B, Higbed L, Nutt D. A review of 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy. Neurosci Lett. 2017;649:84–90. https://doi.org/10.1016/j.neulet.2016.07.004
46. Krebs TS, Johansen PØ. Lysergic acid diethylamide (LSD) for anxiety associated with life-threatening diseases. J Psychopharmacol. 2012;26(7):994–1002. https://doi.org/10.1177/0269881112439253
47. Jerome L, Feduccia AA, Wang JB, et al. Long-term follow-up outcomes of MDMA-assisted psychotherapy. Curr Drug Abuse Rev. 2013;6(1):59–65. https://doi.org/10.2174/18744737112059990005
48. Sessa B, Della Selva MP, Higbed L, Nutt D. MDMA-assisted therapy for treatment-resistant PTSD. J Psychopharmacol. 2021;35(4):375–383. https://doi.org/10.1177/0269881121991792
49. Eurostat. Drug consumption and related harms in the EU [Internet]. Luxembourg: European Commission, 2021; [cited 2026 Jan 31]. Available from: https://ec.europa.eu/eurostat/web/products-eurostat-news/-/edn-20210910-1
50. Kvam S, Stewart LH, Repantis D, Røssberg JI. MDMA-assisted therapy for major depressive disorder: study protocol. Br J Psychiatry. 2025. https://doi.org/10.1192/bjp.2025.10320
51. Wolfson SL, et al. Knowledge and attitudes toward psychedelic-assisted therapy among healthcare professionals. Sci Rep. 2020;10:18619. https://doi.org/10.1038/s41598-020-75706-1
52. Danforth AL, Grob CS, Struble C, et al. Reduction in social anxiety after MDMA-assisted psychotherapy. Psychopharmacology. 2018;235(11):3137–3148. https://doi.org/10.1007/s00213-018-5010-9
53. World Anti-Doping Agency. World Anti-Doping Code: International Standard Prohibited List 2024 [Internet]. Montreal: WADA; 2023 [cited 2026 Mar 25]. Available from: https://www.wada-ama.org/sites/default/files/2023-09/2024list_en_final_22_september_2023.pdf
54. Dunn M, Thomas JO, Swift W, Burns L. Recreational substance use among elite Australian athletes. Drug Alcohol Rev. 2011;30(1):63-68. https://doi.org/10.1111/j.1465-3362.2010.00200.x
55. Atila C, Straumann I, Vizeli P, Beck J, Monnerat S, Holze F, Liechti ME, Christ-Crain M. Oxytocin and the role of fluid restriction in MDMA-induced hyponatremia: A secondary analysis of 4 randomized clinical trials. JAMA Netw Open. 2024;7(11):e2445278. https://doi.org/10.1001/jamanetworkopen.2024.45278
56. Werle I, Bertoglio LJ. Psychedelics: A review of their effects on recalled aversive memories and fear/anxiety expression in rodents. Neurosci Biobehav Rev. 2024;167:105899. https://doi.org/10.1016/j.neubiorev.2024.105899
57. VanderZwaag B, Garcia-Romeu A, Garcia-Barrera MA. Exploring psychedelic use in athletes and their attitudes toward psilocybin-assisted therapy in concussion recovery. Ther Adv Psychopharmacol. 2024;14:20451253241264812. https://doi.org/10.1177/20451253241264812
58. Chang C, Putukian M, Aerni G, Diamond A, Hong G, Ingram Y, Reardon CL, Wolanin A. Mental health issues and psychological factors in athletes: Detection, management, effect on performance and prevention: American Medical Society for Sports Medicine position statement—executive summary. Br J Sports Med. 2020;54(4):216-220. https://doi.org/10.1136/bjsports-2019-101583
59. McDonald C, Losty C, MacCarthy R. An investigation of the psychological status of amateur athletes before and after a triathlon competition. Eur J Sport Sci. 2023;2(3):14-20. https://doi.org/10.24018/ejsport.2023.2.3.83
60. Smith A, Buadze A, Colangelo J, Liebrenz M. A review of mental health issues in high-performance and elite-level cycling. Int J Sports Med. 2023;44(14):1034-1042. https://doi.org/10.1055/a-2145-6355
61. Beable SE. Depressive disorders in athletes. Clin Sports Med. 2024;43(1):53-70. https://doi.org/10.1016/j.csm.2023.06.011
62. Reardon CL. The sports psychiatrist and psychiatric medication. Int Rev Psychiatry. 2016;28(6):606-613. https://doi.org/10.1080/09540261.2016.1190691
63. Bomfim JHGG. Pharmaceutical care in sports. Pharmacy (Basel). 2020;8(4):218. https://doi.org/10.3390/pharmacy8040218
64. Reardon CL, Creado S. Psychiatric medication preferences of sports psychiatrists. Phys Sportsmed. 2016;44(4):397-402. https://doi.org/10.1080/00913847.2016.1216719
65. Edwards CD. Management of mental health challenges in athletes: Screening, pharmacology, and behavioral approaches. Clin Sports Med. 2024;43(1):13-31. https://doi.org/10.1016/j.csm.2023.06.006
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Magdalena Ostaszewska, Milena Majchrzyk, Damian Zienkiewicz, Gabriela Makulec, Karolina Domosud, Weronika Walendziak, Natalia Mordal, Kacper Ściebura, Wiktoria Wiśniewska, Anna Malczyk
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 40
Number of citations: 0
